biotech

These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or...
These are four stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or...
Here are five biotech stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, these are not penny...
These five super-aggressive biotech stocks are all rated Buy at well-known Wall Street firms and are suitable for very aggressive investors that have a high-risk tolerance.
Frequency Therapeutics shares were absolutely crushed on Tuesday but saw a bit of a recovery early Wednesday.
Here are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or...
Rubius Therapeutics was one of Monday’s biggest winners after it announced initial data from its ongoing Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors.
Altimmune has announced additional preclinical data in regards to its single-dose intranasal COVID-19 vaccine candidate, AdCOVID.
Novavax stock jumped to close out the week after the firm announced the final efficacy numbers for its COVID-19 vaccine candidate.
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Gritstone pushed higher on Tuesday after the company reported that it was advancing the development of a second-generation vaccine against SARS-CoV-2.
Aclaris shares more than doubled to start out the week after the company announced positive results from its mid-stage rheumatoid arthritis study.
Lexicon Pharma shares jumped on Thursday morning after the company announced that it received regulatory feedback from the FDA regarding its heart failure treatment.
Arcturus Therapeutics shares took a tumble on Tuesday after the company announced update on its COVID-19 vaccine candidate.
Aprea Therapeutics stock was absolutely crushed to start out the week after the company announced results from its late-stage trial evaluating the safety and efficacy of its treatment for...